+262.0%
AXTI vs GSK
+214.1%
+47.9%
-98.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -8.1% | -0.1% | -8.0% | -8.1% |
| 7D | -10.4% | -1.3% | -9.1% | -10.0% |
| 30D | -25.3% | +2.7% | -28.0% | -26.3% |
| 3M | -52.9% | +2.7% | -55.6% | -54.0% |
| 6M | -68.9% | +3.3% | -72.3% | -70.1% |
| YTD | +135.2% | +6.5% | +128.8% | +122.9% |
| 1Y | +268.4% | +10.7% | +257.7% | +243.4% |
| 3Y | +1,794.6% | +64.4% | +1,730.2% | +1,372.0% |
| 5Y | +327.8% | +46.7% | +281.1% | +240.8% |
| 10Y | +639.6% | +109.4% | +530.3% | +406.0% |
| All | +262.0% | +214.1% | +47.9% | +99.1% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling